Status:
UNKNOWN
An Open Label, Randomized-controlled Trial to Assess Efficacy Safety of HYALODISC With Physical Exercise Program
Lead Sponsor:
Fidia Farmaceutici s.p.a.
Conditions:
Degenerative Disc Disease(DDD)
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The objective of this study is to determine if one single X-ray-guided intradiscal injection of 8 mg/mL of HYALODISC combined with PEP will be more effective than only physical exercise program in pat...
Detailed Description
During the inclusion visit (V0) upon signature of the informed consent, eligible subject will be enrolled. At baseline visit (V1) eligible subjects will then randomly assigned to 1 of 2 treatment grou...
Eligibility Criteria
Inclusion
- Male or female patients aged 18-70 years;
- Written informed consent;
- Willing and able to comply with the protocol for the duration of the study;
- Chronic low back pain for at least 3 months from the screening;
- Patients with at least one lumbar (L1-S1) black disc (Pfirrmann grade III-V) seen on magnetic resonance imaging (MRI) examination (MRI performed within 4 months from the screening visit);
- Low back pain score of at least 5 on a 0-10 NRS at screening;
- Roland-Morris Disability Questionnaire score of at least 9 on the 24-point questionnaire at screening;
- If female of childbearing potential, must have a negative pregnancy test at screening and agree to use a reliable form of contraception throughout the study\*.
- Note: To be considered of non-childbearing potential, females must be surgically sterile or postmenopausal for at least 1 year.
- \* Highly effective birth control methods include: combined hormonal contraception (containing estrogen and progestogen) associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence..
Exclusion
- Cauda equina syndrome;
- Active malignancy or tumours as source of symptoms;
- Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection;
- Previous lumbar spine surgery;
- Evidence of prior lumbar vertebral body fracture;
- Patients with radiculopathy caused by nerve root compression;
- Verbiest Syndrome of Lumbar Spine;
- Spondylolisthesis (\> Grade 1) with or without spondylolysis at the symptomatic level(s);
- Radiological sacroiliac joint involvement;
- Patients with positive response to medial branch block;
- Patients that did physical exercise therapy in the last three months before screening;
- For patients that need to perform a MRI at the screening visit, contraindications to perform the MRI, such as patients carrying cerebral clips or cooling, valvular endoprosthesis with metal components, defibrillators, pacemakers or neurostimulant devices;
- Sacrum-iliac synchondrosis agenesis seen on MRI;
- Patients with symptomatic hernia, sciatica or spinal cord injury:
- Significant systemic disease, including unstable angina, autoimmune disease, rheumatoid arthritis, and muscular dystrophy;
- Congenital or acquired coagulopathy or thrombocytopenia; or currently taking anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications; or undergoing radiation therapy;
- Patients with known allergies, hypersensitivity or intolerance to paracetamol and/or active or inactive excipients of formulation;
- Ongoing or previous participation in another drug or device clinical study within the previous 2 months from the screening;
- Females known to be pregnant or nursing at time of enrolment or with plans to become pregnant within the planned length of follow-up or unwilling to use adequate contraception and conduct a pregnancy test at screening;
- Patients with suspected or known history of hypersensitivity to hyaluronic acid or to hyaluronate preparations or gram-positive bacterial proteins;
- Patients unable to provide a valid informed consent or those acting in an emergency situation..
Key Trial Info
Start Date :
July 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04757038
Start Date
July 2 2021
End Date
December 1 2024
Last Update
October 2 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Unità operativa complessa di Radiologia PO.SS.Trinità
Cagliari, Italy, 09123
2
Centro per la Terapia del Dolore NSI-EOC FMH Anestesiologia S.S.I.P.M.. Ospedale
Viganello, Lugano, Switzerland, CH-6962